Tamaddon Gholamhossein, Geramizadeh Bita, Karimi Mohammad Hossein, Mowla Seyed Javad, Abroun Said
Department of Hematology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Iran J Med Sci. 2016 Jul;41(4):334-9.
Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. MicroRNAs (miRNAs) are endogenous small RNA, which can regulate gene expression at the post-transcriptional level. MiRNA profiling has shown a great potential as novel diagnostic and prognostic biomarkers. The present study was performed at the Nemazee Teaching Hospital (Shiraz, Iran) from 2011 to 2013. The aim of this study was to assess the deregulation of miRNAs profiles in DLBL against hyperplasic reactive lymph node as a normal. This could serve as a biomarker for DLBL. The miRCURY LNA™ microarray was used on the total RNA, which was extracted from formalin-fixed paraffin-embedded tissue of 24 de novo diffuse large B-cell lymphoma patients and 14 normal lymph nodes. The greatest changes were detected in miR-4284 and miR-4484 level in patient's lymphoma samples. These miRNAs can act as a diagnostic biomarker for DLBL.
弥漫性大B细胞淋巴瘤是最常见的非霍奇金淋巴瘤类型。微小RNA（miRNA）是内源性小RNA，可在转录后水平调节基因表达。miRNA谱分析作为新型诊断和预后生物标志物具有巨大潜力。本研究于2011年至2013年在伊朗设拉子的内马齐教学医院进行。本研究的目的是评估弥漫性大B细胞淋巴瘤（DLBL）中miRNA谱相对于正常增生性反应性淋巴结的失调情况。这可作为DLBL的生物标志物。使用miRCURY LNA™微阵列对从24例初发性弥漫性大B细胞淋巴瘤患者的福尔马林固定石蜡包埋组织和14个正常淋巴结中提取的总RNA进行检测。在患者淋巴瘤样本中，miR-4284和miR-4484水平检测到最大变化。这些miRNA可作为DLBL的诊断生物标志物。
